Overview

A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to evaluate the safety and tolerability of SPM 927 when given as iv infusions compared with oral administration of the same dose strengths in subjects who were receiving oral SPM 927 for partial seizures with or without secondary generalization. Trial procedures will include medical history update, physical/ neurological exams, ECGs, blood /urine sample collections and seizure diary completion. Subjects completing the trial will return to the OLE trial to resume dosing with oral SPM 927.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Lacosamide